Pharmakonzern Lilly senkt Ausblick - Abnehmmedikamente unter Erwartung from

Pharmaceutical Giant Lilly Lowers Outlook as Obesity Drugs Fall Short of Expectations

Lilly's obesity drugs, Mounjaro and tirzepatide, have failed to meet sales expectations, prompting the company to lower its financial outlook.

The news sent Lilly's stock price tumbling, and analysts are now questioning the long-term prospects of the company's obesity franchise.

Mounjaro, which was approved by the FDA in May 2022, has been hailed as a potential blockbuster drug.

The drug, which is a once-weekly injection, has shown promising results in clinical trials, helping patients lose significant amounts of weight. However, sales of Mounjaro have been slower than expected, and Lilly has now lowered its sales forecast for the drug.

Tirzepatide, which is still in the clinical trial phase, has also failed to meet expectations.

The drug, which is a once-daily injection, has shown similar efficacy to Mounjaro in clinical trials. However, Lilly has now announced that it will delay the filing of a marketing application for tirzepatide with the FDA. The disappointing sales of Mounjaro and tirzepatide are a major blow to Lilly, which has invested heavily in the development of obesity drugs. The company is now facing pressure from investors to improve the sales of its obesity drugs and to deliver on the promise of its obesity franchise.

Lilly's lowered outlook is a reminder of the challenges facing the obesity drug market.

Obesity is a complex disease, and there is no easy solution. Despite the advances in obesity drug development, there is still a need for more effective and affordable treatments. Lilly is not the only company facing challenges in the obesity drug market. Novo Nordisk, another major player in the market, has also seen its sales of obesity drugs fall short of expectations. The challenges facing the obesity drug market are a reminder of the need for more research and development in this area. There is a need for new drugs that are more effective, more affordable, and have fewer side effects. With continued research and development, there is hope that the obesity drug market will eventually deliver on its promise of helping people lose weight and improve their health.